P. A-M retweeted
In medicine we say “recommendations as per our prior notes; thank you for this interesting consult, signing off”
P. A-M retweeted
🤝Los oncólogos en Europa (@myESMO) y EEUU (@ASCO) se alían para ❌reducir la 📃burocracia de los 🧪ensayos clínicos.
👉Estiman que los investigadores recogen entre 10 y 20 veces más información de la necesaria.
diariomedico.com/medicina/on…
P. A-M retweeted
📢Nuevos resultados de fase III muestran una alta eficacia de 💉tezepelumab, de @AstraZeneca y @Amgen, en esofagitis eosinofílica 👇.
diariomedico.com/medicina/al…
P. A-M retweeted
💡#ESMO26 I ➡️Durvalumab más enfortumab vedotin reduce un 42% el riesgo de muerte en cáncer de vejiga músculo-invasivo no candidato a cisplatino. @myesmo. diariomedico.com/medicina/on…
P. A-M retweeted
Continuous in situ production of CAR T-cells from in vivo-transduced HSCs is safe and mediates delay in growth of mouse HER2high tumors. dlvr.it/TW4Pjk
P. A-M retweeted
This study led by first author Lizhong Yao identified a stromal-mediated metabolic immune evasion pathway in #gastrointestinal tumors, uncovering a potential strategy to potentiate CAR-engineered therapies. | @CR_AACR
Give it a read: bit.ly/4Bw2Faw
P. A-M retweeted
In Phase 1, Incyte’s KRAS G12D inhibitor plus standard-of-care chemotherapy yielded an 89% confirmed objective response rate in patients with a type of pancreatic ductal adenocarcinoma, prompting analyst comparisons with Revolution Medicines’ zoldonrasib.
hubs.li/Q04CsThV0
P. A-M retweeted
🇪🇺La @EMA_News da luz verde a 'Foundayo', primer #GLP1 en pastilla de toma única diaria, de @EliLillyandCo.
🇺🇸La @US_FDA lo autorizó en abril.
💊Se puede ingerir a cualquier hora y sin ayuno previo ni posterior.
✍️@CarmenTorrenteV
diariomedico.com/farmacia/in…
P. A-M retweeted
A more than 40% risk reduction “would send many researchers over the Moon”. This personalised mRNA vaccine reduced the risk of skin cancer returning or the recipient dying by 42%
go.nature.com/4zIVp9E
P. A-M retweeted
With our partners at @Merck, we announced detailed results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized neoantigen therapy, in combination with pembrolizumab, in patients with completely resected stage IIB-IV melanoma.
Presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026, these findings offer important insights into the potential of individualized cancer treatment.
Read more: modernatx.com/recapping-the-…
P. A-M retweeted
🚨 New research alert! 🚨
@KitePharma scientists analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel from 580 patients with non-Hodgkin lymphoma across multiple clinical trials. Their work has the potential to advance the development of more effective #CellularTherapies!
Congratulations to Justin Budka, Madison Davis, Davide Bedognetti, and colleagues!
Read the full @NatureMedicine article 👉 go.nature.com/4zhszxa.
P. A-M retweeted
Nature research paper: Programmable design of functional proteins from natural language
go.nature.com/47xbVh8
P. A-M retweeted
RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.
hubs.li/Q04C93FG0
P. A-M retweeted
A more than 40% risk reduction “would send many researchers over the Moon”. This personalised mRNA vaccine reduced the risk of skin cancer returning or the recipient dying by 42%
go.nature.com/4izbJnE
P. A-M retweeted
A powerful gene-editing technique has been used to edit DNA directly in a person’s body — the first known instance of such a treatment.
go.nature.com/4Bgi3Yx
P. A-M retweeted
Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model
The @UWproteindesign has partnered with @nvidia to develop an open, generative model that uses biomolecular reasoning for protein design
#GENEdge #AI #proteins
hubs.li/Q04C7YC90
P. A-M retweeted
🥳 Congratulations to @MIT's Dr. Daniel Anderson, Dr. Yuang Chen, Julia Monkovic, Haseeb Mughal, and colleagues on their recent @NatureBiotech paper!
They developed a new way to program #NaturalKiller immune cells to target cancerous T cells or T cells that have become autoreactive, leading to diseases such as lymphoma and autoimmune hepatitis.
Article | go.nature.com/4jI5m2D
Press Release | bit.ly/4hS8ZjC
P. A-M retweeted
This Review in the October issue discusses insights from clinical studies on mRNA-based therapeutics, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies
nature.com/articles/s41573-0…
rdcu.be/7oahN7b3b3Ha
P. A-M retweeted
📖 Read this @Cancer_Cell review where @StanfordMed researchers summarize the clinical lessons learned from commercial chimeric antigen receptor T cell therapy and clinical trials, and discuss three waves shaping next-generation development.
🔗 bit.ly/3TQDSgF
P. A-M retweeted
A phase 1 trial shows that treatment of patients with high-grade serous ovarian cancer with personalized neoantigen vaccines combined with PD-1 blockade was feasible and led to tumor-specific immune responses in many patients.
@DFCI_NeoVax